Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TARS1 | P26639 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445424 | 0.88 | MMP2 (0.61) | ALDH1A1MMP1MMP13MMP2ADAMTS4 | |
| SCHEMBL5445643 | 0.87 | ALDH1A1 (0.51) | ALDH1A1PKMHPGDALOX12MMP1 | |
| SCHEMBL14565748 | 0.84 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDALOX12MMP1 | |
| SCHEMBL6557790 | 0.81 | MMP1 (0.50) | ALDH1A1PKMHPGDALOX12MMP1 | |
| SCHEMBL6557786 | 0.79 | ALDH1A1 (0.48) | ALDH1A1PKMHPGDALOX12MMP1 | |
| SCHEMBL5445420 | 0.74 | MMP2 (0.61) | MMP1MMP13MMP2ADAMTS4MMP14 | |
| SCHEMBL6558732 | 0.73 | MMP1 (0.50) | ALDH1A1HPGDMMP1MMP13MMP2 | |
| SCHEMBL14565746 | 0.70 | MMP2 (0.56) | MMP1MMP13MMP2ADAMTS4MMP14 | |
| SCHEMBL6558726 | 0.70 | TBXAS1 (0.49) | ALDH1A1PKMMMP1MMP13MMP2 | |
| SCHEMBL6558721 | 0.70 | TBXAS1 (0.49) | ALDH1A1PKMMMP1MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | claimed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | claimed |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | ALDH1A1 3814/4885PKM 4607/4885HPGD 1476/4885 |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | ALDH1A1 3814/4885PKM 4607/4885HPGD 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.